A single ALS center experience with clinical use of sodium phenylbutyrate-taurursodiol.

Colin C QuinnMichael BaerDefne A AmadoMary KelleyLauren Elman

Published in: Muscle & nerve (2024)

PB-TURSO was approved by insurance for most patients. The discontinuation rate was high and was driven largely by GI side effects and taste. Future considerations would include deeper examination of demographic trends, patient costs, side effects, and potential benefits in clinical practice.

Keyphrases

clinical practice
end stage renal disease
newly diagnosed
peritoneal dialysis
prognostic factors
case report
health insurance
risk assessment
patient reported outcomes
human health